Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
- PMID: 30076539
- PMCID: PMC6153967
- DOI: 10.1007/s40263-018-0554-0
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
Erratum in
-
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.CNS Drugs. 2018 Dec;32(12):1185. doi: 10.1007/s40263-018-0585-6. CNS Drugs. 2018. PMID: 30421245 Free PMC article.
Abstract
Background: ALZ-801 is an oral, small-molecule inhibitor of beta amyloid (Aβ) oligomer formation in clinical development for Alzheimer's disease (AD). ALZ-801 is a prodrug of tramiprosate with improved pharmacokinetic properties and gastrointestinal tolerability. During clinical studies, we discovered that the primary metabolite of tramiprosate and its prodrug ALZ-801, 3-sulfopropanoic acid (3-SPA), is an endogenous molecule in the human brain and present in the cerebrospinal fluid (CSF) of patients with AD and other neurodegenerative brain diseases.
Objective: The objectives of this research were to (1) identify and confirm the presence of 3-SPA in CSF samples from elderly, drug-naïve patients with memory deficits; (2) quantify the levels of 3-SPA in the CSF of patients with AD from tramiprosate phase III North American (NA) trial; (3) evaluate the in vitro anti-Aβ42 oligomer activity of 3-SPA; and (4) characterize the pharmacokinetics and brain-penetration properties of 3-SPA.
Methods: Lumbar CSF samples from 64 drug-naïve patients with cognitive deficits (Mini-Mental State Examination [MMSE] score range 15-30) and six patients with AD treated with tramiprosate 150 mg twice daily in the phase III trial, at week 78, were analyzed. We used liquid chromatography-tandem mass spectrometry to confirm the structural molecular identity of endogenous 3-SPA with a 3-SPA reference standard and ion-mobility spectrometry-mass spectrometry with molecular dynamics to characterize interactions of 3-SPA with Aβ42 monomers, and the resultant conformational alterations. Rat studies using oral (30 mg/kg) and intravenous (10 mg/kg) doses were conducted to characterize the pharmacokinetic properties and brain penetration of 3-SPA.
Results: We confirmed the presence of 3-SPA in the CSF of drug-naïve patients with cognitive deficits (mean concentration 11.7 ± 4.3 nM). The mean concentration of 3-SPA in patients with AD treated with tramiprosate was 135 ± 51 nM. In vitro studies revealed a multi-ligand interaction of 3-SPA with monomeric Aβ42 that inhibits the aggregation of Aβ42 into small oligomers. Comparisons of the molecular interactions of tramiprosate and 3-SPA with Aβ42 are also presented. Furthermore, in rat preclinical studies, 3-SPA displayed 100% oral bioavailability and 25% brain penetration, indicating that the metabolite is well absorbed and crosses the blood-brain barrier.
Conclusions: We confirmed the endogenous presence of 3-SPA, the major metabolite of tramiprosate, in the CSF of drug-naïve elderly patients with memory deficits due to AD and a variety of other neurodegenerative disorders. The levels of 3-SPA were up to 12.6-fold greater in patients with AD receiving tramiprosate than in drug-naïve patients. In addition, we showed that 3-SPA has potent anti-Aβ oligomer activity, inhibiting aggregation of Aβ42 into small oligomers with efficacy comparable to that of tramiprosate. 3-SPA displays excellent oral availability and brain penetration in rats, suggesting that the higher CSF concentrations of 3-SPA in the human brain after oral administration of ALZ-801 or tramiprosate (and subsequent conversion to 3-SPA) result from the penetration of the metabolite into the central nervous system. These data suggest that 3-SPA is an endogenous agent with potential activity stabilizing the conformational flexibility of Aβ monomers that, in turn, inhibit Aβ misfolding and formation of soluble toxic Aβ oligomers in humans, thereby preventing the initial pathogenic step in the progression of AD. Clinical improvements observed in patients with AD carrying the ε4 allele of the apolipoprotein E gene in tramiprosate phase III studies may in part be explained by the therapeutic effects of excess levels of the metabolite in the brains of these patients. The potential protective role of 3-SPA in AD pathogenesis, as well as its therapeutic role in AD and other neurodegenerative disorders, warrants further investigation.
Conflict of interest statement
John A. Hey, Petr Kocis, Susan Abushakra, Aidan Power, and Martin Tolar are employees of Alzheon, Inc., and own Alzheon stock options. Jeremy Y. Yu serves as a consultant to Alzheon and owns Alzheon stock options. Jakub Hort and Martin Vyhnálek are independent clinical investigators who collaborated on the study. Dr. Jakub Hort is a member of the Alzheon Scientific Advisory Board and owns Alzheon stock options.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6153967/bin/40263_2018_554_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6153967/bin/40263_2018_554_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6153967/bin/40263_2018_554_Fig3_HTML.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6153967/bin/40263_2018_554_Fig4_HTML.gif)
![Fig. 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6153967/bin/40263_2018_554_Fig5_HTML.gif)
![Fig. 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6153967/bin/40263_2018_554_Fig6_HTML.gif)
![Fig. 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6153967/bin/40263_2018_554_Fig7_HTML.gif)
![Fig. 8](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6153967/bin/40263_2018_554_Fig8_HTML.gif)
![Fig. 9](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6153967/bin/40263_2018_554_Fig9_HTML.gif)
Similar articles
-
Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer's disease: a novel small molecule with disease modifying potential.Expert Opin Pharmacother. 2024 May;25(7):791-799. doi: 10.1080/14656566.2024.2360069. Epub 2024 May 30. Expert Opin Pharmacother. 2024. PMID: 38814590 Review.
-
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w. Alzheimers Res Ther. 2020. PMID: 32787971 Free PMC article. Review.
-
Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.J Prev Alzheimers Dis. 2017;4(3):149-156. doi: 10.14283/jpad.2017.26. J Prev Alzheimers Dis. 2017. PMID: 29182706 Clinical Trial.
-
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.Clin Pharmacokinet. 2018 Mar;57(3):315-333. doi: 10.1007/s40262-017-0608-3. Clin Pharmacokinet. 2018. PMID: 29063518 Free PMC article. Clinical Trial.
-
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.CNS Drugs. 2017 Jun;31(6):495-509. doi: 10.1007/s40263-017-0434-z. CNS Drugs. 2017. PMID: 28435985 Free PMC article.
Cited by
-
Combination of Tramiprosate, Curcumin, and SP600125 Reduces the Neuropathological Phenotype in Familial Alzheimer Disease PSEN1 I416T Cholinergic-like Neurons.Int J Mol Sci. 2024 Apr 30;25(9):4925. doi: 10.3390/ijms25094925. Int J Mol Sci. 2024. PMID: 38732141 Free PMC article.
-
The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.Int J Mol Sci. 2024 Feb 27;25(5):2727. doi: 10.3390/ijms25052727. Int J Mol Sci. 2024. PMID: 38473975 Free PMC article. Review.
-
Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.Int J Mol Sci. 2023 Sep 9;24(18):13900. doi: 10.3390/ijms241813900. Int J Mol Sci. 2023. PMID: 37762203 Free PMC article. Review.
-
Druggable targets for the immunopathy of Alzheimer's disease.RSC Med Chem. 2023 Jul 11;14(9):1645-1661. doi: 10.1039/d3md00096f. eCollection 2023 Sep 19. RSC Med Chem. 2023. PMID: 37731705 Free PMC article. Review.
-
Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer's Disease drug candidate.Mol Neurodegener. 2023 Jun 6;18(1):38. doi: 10.1186/s13024-023-00620-9. Mol Neurodegener. 2023. PMID: 37280636 Free PMC article.
References
-
- Hey JA, Yu Jeremy Y, Versavel M, Abushakra A, Kocis P, Power A, Kaplan PL, Amedio J, Tolar M. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2018;57:315–333. doi: 10.1007/s40262-017-0608-3. - DOI - PMC - PubMed
-
- Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA. Elucidating the Abeta42 anti-aggregation mechanism of action of tramiprosate in Alzheimer’s disease: integrating molecular analytical methods. Pharmacokinetic and clinical data. CNS Drugs. 2017;31:495–509. doi: 10.1007/s40263-017-0434-z. - DOI - PMC - PubMed
-
- Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M. Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer’s disease suggest disease modification potential. J Prev Alzheimers Dis. 2017;4:149–156. - PubMed
-
- Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Hendrix S, Wang P, Shen L, Sampalis J, Tolar M. Clinical benefits of tramiprosate in Alzheimer’s disease are associated with higher number of APOE4 alleles: the ‘‘APOE4 gene-dose effect’’. J Prev Alz Dis. 2016;3:219–228. - PubMed
-
- Alzheimer’s disease facts and figures. Alzheimer’s Dement 2018;14(3):367–429.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical